Nitazene Addiction Treatment in Chiang Mai, Thailand
Nitazenes are a class of synthetic opioids appearing in street drug supplies across Asia, Europe, and North America, with potency ranging from fentanyl-equivalent to several times above it. Withdrawal follows standard opioid patterns and is medically manageable. Jintara offers medical detox and opioid addiction treatment in Chiang Mai for people whose substance use includes nitazenes. 10 clients. 32 staff. 24/7 awake nursing.
Fully Licensed and Hospital Accredited
Nitazenes Are a Class of Synthetic Opioids, Not a Single Drug.
Nitazene addiction is dependence on a class of synthetic mu-opioid receptor agonists that carry fentanyl-range potency and extreme overdose risk. The class includes isotonitazene, metonitazene, protonitazene, etonitazene, and several others, originally developed as research analgesics in the 1950s and now re-emerging in the illicit drug supply. Potency varies by compound. Isotonitazene is broadly fentanyl-equivalent, while some members of the class exceed fentanyl by a factor of two to ten. Because batch composition is unknown to the person using them, the overdose risk from a single exposure is unpredictable in a way that heroin and prescription opioids generally are not.
Nitazenes are appearing in three main forms. They are pressed into counterfeit pills designed to resemble prescription opioids such as oxycodone or hydrocodone, used to adulterate or replace heroin in supply chains where fentanyl availability is inconsistent, and dissolved into benzodiazepine-laced street preparations that raise respiratory depression risk sharply. Most people who have used nitazenes do not know it, because the compound is not printed on any label and is rarely identified without laboratory testing, a pattern tracked in NIDA's emerging drug trends resource.
For medical detox purposes, this matters because the person presenting for admission may underestimate the potency of what they have been using, leading to a withdrawal picture that does not match the reported substance history. Jintara's nursing team is trained to watch for this mismatch at the initial assessment.
How Nitazenes Compare to Other Street Opioids
| Opioid | Relative potency | Why the overdose risk differs |
|---|---|---|
| Heroin | Baseline street opioid | Dose varies but is broadly familiar to a regular user |
| Fentanyl | 50 to 100 times morphine | A tiny margin between an active dose and a lethal one |
| Nitazenes | Fentanyl-equal to ten times higher | Concentration is unknown and changes between batches |
Heroin
Relative potency: Baseline street opioid
Why the overdose risk differs: Dose varies but is broadly familiar to a regular user
Fentanyl
Relative potency: 50 to 100 times morphine
Why the overdose risk differs: A tiny margin between an active dose and a lethal one
Nitazenes
Relative potency: Fentanyl-equal to ten times higher
Why the overdose risk differs: Concentration is unknown and changes between batches
The Overdose Risk From Nitazenes Is Driven by Unknown Concentration, Not Just Potency.
The primary danger with nitazene exposure is not simply that the compounds are potent. It is that potency per unit is unknown and varies significantly between batches. A person who has developed a tolerance calibrated to one potency level may encounter a nitazene-laced preparation at two or five times that potency without warning. Respiratory depression is the mechanism of harm. The brain's opioid receptors suppress the drive to breathe, and at high enough doses, breathing stops.
This is the same mechanism that makes fentanyl dangerous, and nitazenes are an extension of the same crisis rather than a separate phenomenon. Fentanyl is 50 to 100 times more potent than morphine, street opioid dosing is uncontrolled, and the overdose risk is the highest of all opioids, as NIDA's overview of fentanyl and synthetic opioids sets out. The difference with nitazenes is that they are newer, appear in counterfeit pills in addition to the powder supply, and are more likely to be encountered without any awareness that they are present.
The polysubstance combination that carries the highest overdose risk is opioids plus benzodiazepines. Taken together they produce compounding respiratory depression and are a leading cause of overdose deaths in North America. Nitazene preparations frequently contain benzodiazepines, which is why someone presenting with opioid withdrawal symptoms should always be assessed for concurrent benzodiazepine dependence.
Withdrawal From Nitazenes Follows Standard Opioid Withdrawal and Is Medically Manageable.
Nitazene withdrawal is opioid withdrawal. The receptor mechanism is the same as heroin and prescription opioids, which means the symptom picture, the scoring tools, and the medication options are established and effective. Jintara uses the Clinical Opiate Withdrawal Scale (COWS) to score withdrawal severity from admission through the acute phase. COWS measures eleven objective signs including pulse rate, sweating, pupil size, gastrointestinal distress, restlessness, tremor, and anxiety, and the score guides medication decisions and monitoring frequency.
Monitoring cadence follows those COWS scores. The vitals and withdrawal monitoring run three times daily in the first three to four days when the score is high, reduce to twice daily as scores fall, then once daily to stable. Where scoring is elevated, a psychiatrist-led methadone taper stabilises the client and reduces withdrawal symptoms to a manageable level, and COWS is the validated instrument for scoring opioid withdrawal in clinical settings. The nursing team observes how the client presents through the day and at night, documents symptom scores, and feeds that back to the psychiatrist for medication review.
Initial assessment at admission includes vital signs, COWS scoring, a urine drug screen, and a health review to identify any conditions that could complicate the withdrawal course. Opioid withdrawal is uncomfortable but not life-threatening in itself for most presentations, though untreated severe withdrawal in the context of polysubstance dependence can carry additional risk. The acute phase for most opioid presentations peaks between days three and five and substantially resolves within seven to ten days.
“Opioid withdrawal is hard physically. But if the medication plan is right and the monitoring is consistent, people move through it. What they need to know is that it is manageable and that the team is watching.
The 30-Day Program for Synthetic Opioid Withdrawal Runs in Three Clinical Phases.
The 30-day program at Jintara for opioid addiction follows a structured sequence across three clinical phases. The first is medical stabilisation, which for most synthetic opioid presentations occupies the first week, where the priority is physical safety, symptom management, and building the client's confidence that they can move through withdrawal with the team's support.
As COWS scores fall and the client's physical state settles, structured therapy starts in full and runs through the middle of the program, and discharge preparation closes the stay. From admissions onward, clients with synthetic opioid histories are assessed for length of stay the same way as any opioid presentation, and where concurrent benzodiazepine dependence is present a longer stay may be recommended.
- Phase one, medical stabilisation: Acute opioid withdrawal, managed with a COWS-guided methadone taper and 24/7 nursing through the first week.
- Phase two, structured therapy: Individual sessions, group work, and trauma-informed treatment, with psychoeducation on the opioid supply, tolerance, and overdose risk at re-exposure.
- Phase three, discharge preparation: A written aftercare plan, support structures identified at home, and overdose education covering what happens to tolerance after abstinence.
Thirty days is the standard. Where a client needs longer, the stay extends by agreement between the client and the clinical team rather than to a fixed block.
The Nitazene and Benzodiazepine Combination Requires Dual-Stream Assessment at Admission.
One of the most significant clinical challenges in nitazene addiction treatment is that nitazenes frequently arrive in the supply mixed with or alongside benzodiazepines. This matters at the treatment stage because benzodiazepine dependence produces its own withdrawal picture, and that withdrawal can include seizures if not properly managed. A client who reports opioid use may arrive with concurrent benzodiazepine dependence that was not part of their intended substance use.
Jintara's assessment protocol at admission includes a multi-panel urine drug screen specifically to catch undisclosed or unknown substances. Where concurrent benzodiazepine dependence is identified, the treatment plan addresses both streams, because opioids and benzodiazepines together are the leading overdose combination in the illicit supply and are increasingly laced into street drugs without the user's knowledge.
Opioid withdrawal and benzodiazepine withdrawal have different timelines and medication approaches. Managing them together requires a psychiatrist-led plan that sequences medication safely. The risks of attempting this combination without medical supervision are the primary reason home detox is not recommended for anyone with opioid or benzodiazepine dependence.
The 24/7 Nursing Model Is the Safety Layer That Makes Opioid Detox Safe.
Medical detox at Jintara runs 24 hours a day with registered nurses awake overnight, not on call. Clients in early detox are checked every one to two hours, vital signs are documented, and reports are provided to management daily. Clients in acute opioid detox are typically assessed three times daily in the first three to four days, moving to twice daily as COWS scores fall, then once daily as they stabilise.
The overnight nursing presence is not a comfort feature. It is the mechanism by which withdrawal complications are caught before they escalate, and the hospital escalation criteria set out exactly when a situation moves beyond what the facility manages on site. Some clients who have been using polysubstance combinations develop complications the team did not anticipate from the admission history alone, and the nurse who is awake and checking clients at 2am is the first line of intervention.
When a situation does require hospital escalation, Jintara's confirmed transfer partners are Bangkok Hospital Chiang Mai and RAM Hospital. Transfer decisions are made by nursing and clinical staff based on symptom presentation. The team's operational principle is that any client or nursing concern triggers an evaluation, including in the middle of the night.
Jintara Treats the Opioid Supply as It Is Now, Not as It Was.
Jintara treats the opioid supply as it is, not as it was five years ago. For people whose use includes synthetic opioids of uncertain composition, that means transparent clinical guidance, honest acknowledgement of what is not yet established in the literature, and opioid detox protocols that apply whether the specific compound is heroin, fentanyl, or isotonitazene. The receptor mechanism is the same, the treatment is the same, and the safety infrastructure is the same.
For people with opioid addiction whose recent use may include synthetic compounds they cannot identify, the clinical response at Jintara is consistent. The team assesses what is present, builds the medication plan from what is found, monitors closely, and begins therapy alongside detox from day one. The specific compound does not change the shape of the response.
Waiting for a drug class to reach crisis level before acknowledging it serves no one searching for information now. That is the reason this page exists, and the reason a person whose supply may include something they cannot name still has somewhere to find a clear clinical answer.
“If someone calls us because they have been using something they cannot identify, or something they think might be a synthetic opioid, we want them to know: we can treat it. The protocol is established. Come in.
Re-Exposure Risk After Treatment Is the Highest Overdose Risk Window for Synthetic Opioid Users.
Re-exposure risk is the clinical reality that opioid tolerance drops rapidly during abstinence, so a person returning to opioid use after treatment faces overdose risk on a dose that would not have been dangerous before admission. For synthetic opioids of unknown potency, that risk is compounded because the supply available after discharge may be stronger than what the person was using before treatment.
This is why aftercare and relapse prevention begin in week one of the program, not in the final days before discharge. Research on post-treatment outcomes shows the first 30 days after leaving residential opioid treatment are the highest-risk window for fatal overdose, because reduced tolerance meets an unchanged or stronger supply.
Jintara does not provide naloxone kits at discharge, and methadone is used during detox for the withdrawal taper only, not for long-term maintenance. What the program does provide is overdose education, a direct clinical conversation about tolerance loss during abstinence, what the risk looks like in the first month after discharge, and the choices that reduce it.
Talk with Our Admissions Team
Your enquiry is confidential and goes only to our admissions team.
Independently Verified
Jintara is accredited against Thailand’s national quality standard for drug treatment and rehabilitation facilities, jointly certified by the Healthcare Accreditation Institute, the body that accredits Thailand’s hospitals, with the Princess Mother National Institute on Drug Abuse Treatment and the Department of Medical Services, Ministry of Public Health. Certificate no. 25/2569, valid 20 May 2026 to 19 May 2029.
Common Questions About Nitazene Addiction Treatment
Nitazenes are a class of synthetic opioids, not a single drug. The class includes isotonitazene, metonitazene, protonitazene, and others. They were originally developed as research analgesics in the 1950s and have reappeared in the illicit drug supply over the past decade, most commonly in counterfeit pills or as adulterants in heroin supply chains. Most people exposed to nitazenes do not know they have taken one.
Potency varies by compound. Isotonitazene is broadly fentanyl-equivalent. Some nitazene compounds are estimated to be two to ten times more potent than fentanyl. Because batch composition is unknown, the potency of any given exposure is unpredictable. This is the primary reason overdose risk from nitazenes is considered extreme relative to other opioids.
Naloxone can reverse a nitazene overdose because it is a non-selective opioid antagonist. Some nitazene compounds may require higher doses or repeated administration compared with a heroin overdose. The clinical concern is that bystanders may not administer enough, or may assume recovery is complete after one dose when respiratory depression has not fully resolved.
This is possible and has been documented in multiple countries. Nitazenes have been found in heroin samples, in counterfeit pills, and in benzodiazepine preparations. The illicit opioid supply in many markets now contains multiple compounds, and the person using them has no reliable way to identify composition without laboratory testing.
Yes. Nitazene withdrawal is opioid withdrawal. The mechanism is the same and the clinical tools are the same: COWS-based withdrawal scoring, a psychiatrist-led methadone taper, and 24/7 nursing monitoring. The assessment at admission includes a multi-panel urine drug screen to identify what is present. The treatment plan is built from what is found, not from what was reported.
Acute opioid withdrawal for most compounds peaks between days three and five and substantially resolves within seven to ten days. Post-acute withdrawal symptoms, including sleep disruption, low mood, and opioid cravings, can continue for weeks to months. The first week of the program is focused on moving through the acute phase safely. Therapy begins alongside detox from day one and becomes the primary focus once the client is physically stable.
Because people affected by synthetic opioid use need somewhere to find clear clinical information. Waiting until a drug class reaches crisis level before acknowledging it leaves a gap that serves no one searching for information now. Jintara treats the opioid supply as it is, not as it was five years ago.
The admission protocol is the same as any opioid presentation: urine drug screen, vital signs, COWS scoring, and a health review. If nitazene is identified or suspected, the withdrawal management plan follows standard opioid protocol. The clinical team adapts medication decisions to what is observed, not only to what was disclosed.
Nitazene compounds have been identified in the drug supply in several Asian countries. Whether they are present in the Thai supply is not confirmed by Jintara's clinical team at the time of publication. This page addresses the possibility because people arriving in Thailand from other countries may have active nitazene exposure histories, and because the opioid supply evolves faster than most clinical guidance.
Yes. Jintara accepts international clients from across Asia, Australia, the UK, and Europe. The admissions team reviews each case before arrival to ensure the clinical team is prepared for the presenting substance history. To discuss a specific situation, contact admissions directly through the Jintara website.
Jintara treats nitazene and synthetic opioid dependence alongside heroin, fentanyl, and benzodiazepine addiction in Chiang Mai, Thailand.